ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism
REVIEW

Relationship Between Sarcopenia and Type 2 Diabetes Mellitus in Elderly Patients
Yaşlı Hastalarda Sarkopeni ve Tip 2 Diabetes Mellitus Arasındaki İlişki
Doi: 10.25179/tjem.2018-62624 - Makale Dili: EN
Turk J Endocrinol Metab 2019;23:47-52
ABSTRACT
Sarcopenia has been defined as a condition of decreased muscle strength, as measured by gait speed and grip strength, in the presence of low muscle mass. It is also known that the total muscle mass generally decreases by 1% after the age of 40 years. Type 2 diabetes mellitus (T2DM) is a global health concern that has continued to affect people even during 2018; its prevalence increases with age. Among the several factors that lead to sarcopenia in elderly patients, insulin resistance is one. However, it is still not clear whether this resistance is a coincidence or a consequence of diabetes. Common pathophysiological mechanisms between sarcopenia and diabetes make it difficult to distinguish the order of development of sarcopenia and T2DM. Prospective studies have demonstrated that low muscle mass and muscle strength may be associated with the development of T2DM. It has also been shown that T2DM exacerbates sarcopenia in elderly T2DM patients. Nevertheless, further research is needed to ascertain the exact nature of the relationship between sarcopenia and T2DM, so that their underlying causes may be minimized.
ÖZET
Sarkopeni, düşük kas kütlesinin varlığında yürüyüş hızı ve kavrama gücü ile ölçülen azalmış kas gücü durumu olarak tanımlanmıştır. Ayrıca, toplam kas kütlesinin 40 yaşından sonra genellikle %1 azaldığı da bilinmektedir. Tip 2 diabetes mellitus (Tip 2 DM), 2018 yılında hala insanları etkilemeye devam eden küresel bir sağlık sorunudur ve prevalansı yaşla birlikte artmaktadır. Yaşlı hastalarda sarkopeniye yol açan çeşitli faktörler arasında insülin direnci de bulunmaktadır. Bununla birlikte, bu direncin bir rastlantı mı yoksa diyabetin bir sonucu mu olduğu hâlâ net değildir. Sarkopeni ve diyabet arasındaki yaygın ortak patofizyolojik mekanizmalar sarkopeni ve Tip 2 DM gelişim sırasını ayırt etmeyi zorlaştırmaktadır. Prospektif çalışmalar, düşük kas kütlesinin ve kas gücünün Tip 2 DM'nin gelişimi ile ilişkili olabileceğini göstermiştir. Tip 2 DM varlığının yaşlı Tip 2 DM hastalarında sarkopeniyi artırdığı da gösterilmiştir. Bununla birlikte, sarkopeni ve Tip 2 DM arasındaki ilişkinin kesin doğasını saptamak için daha fazla detaylı araştırmaya ihtiyaç olduğu aşikârdır.
KAYNAKLAR
  1. Diabetes UK. Diabetes: Facts and stats. Diabetes UK Care Connect Campaign; 2014:17. [Link]
  2. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gen- der differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37:278-316. [Crossref]  [PubMed]  [PMC]
  3. King H,  Aubert RE, Herman  WH. Global burden  of diabetes, 1995-2025: prevalence,  numerical esti- mates, and  projections. Diabetes Care. 1998;21:1414-1431. [Crossref]   [PubMed]
  4. Manco M, Nolfe G, Calvani M, Natali A, Nolan J, Fer- rannini E, Mingrone G; European Group for the Study of Insulin Resistance. Menopause, insulin resistance, and risk factors for cardiovascular disease. Menopause. 2006;13:809-817. [Crossref]  [PubMed]
  5. Von Korff M, Katon W, Lin EH, Simon G, Ciechanowski P, Ludman E, Oliver M, Rutter C, Young B. Work disability among individuals with diabetes. Diabetes Care. 2005;28:1326-1332. [Crossref]  [PubMed]
  6. Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Newman AB. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes. 2006;55:1813-1818. [Crossref]  [PubMed]
  7. Tsugawa A,  Ogawa Y,  Takenoshita N, Kaneko  Y, Hatanaka H,  Jaime E, Fukasawa  R, Hanyu H.  De- creased muscle strength  and quality in  diabetes-re- lated dementia. Dement  Geriatr Cogn Dis  Extra. 2017;7:454-462. [Crossref]   [PubMed]   [PMC]
  8. Dennis RA, Przybyla B, Gurley C, Kortebein PM, Simpson P, Sullivan DH, Peterson CA. Aging alters gene expression of growth and remodeling factors in human skeletal muscle both at rest and in re- sponse to acute resistance exercise. Physiol Ge- nomics. 2008;32:393-400. [Crossref]  [PubMed]
  9. Zahn JM, Sonu R, Vogel H, Crane E, Mazan-Mam- czarz K, Rabkin R, Davis RW, Becker KG, Owen AB, Kim SK. Transcriptional profiling of aging in human muscle reveals a common aging signature. PLoS Genet. 2006;2:e115. [Crossref]  [PubMed]  [PMC]
  10. Punkt K, Psinia I, Welt K, Barth W, Asmussen G. Ef- fects on skeletal muscle fibres of diabetes and Ginkgo biloba extract treatment. Acta Histochem. 1999;101:53-69. [Crossref]
  11. Janssen I, Ross R. Linking age-related changes in skeletal muscle mass and composition with metabolism and disease. J Nutr Health Aging. 2005;9:408-419. [PubMed]
  12. Furler SM,  Poynten AM, Kriketos  AD, Lowy AJ,  Ellis BA, Maclean EL,  Courtenay BG, Kraegen  EW, Camp- bell LV,  Chisholm DJ. Independent  influences of cen- tral fat and  skeletal muscle lipids  on insulin sensitivity. Obes  Res. 2001;9:535-543. [Crossref]  [PubMed]
  13. Rasmussen BB, Fujita S, Wolfe RR, Mittendorfer B, Roy M, Rowe VL, Volpi E. Insulin resistance of mus- cle protein metabolism in aging. FASEB J. 2006;20:768-769. [Crossref]  [PubMed]  [PMC]
  14. Möller-Loswick AC, Zachrisson  H, Hyltander A, Körner U,  Matthews DE, Lundholm K.  Insulin selec- tively attenuates breakdown  of nonmyofibrillar pro- teins in  peripheral tissues of normal  men. Am J Physiol. 1994;266:E645-E652.  [PubMed]
  15. Nygren J, Nair KS. Differential regulation of protein dynamics in splanchnic and skeletal muscle beds by insulin and amino acids in healthy human subjects. Diabetes. 2003;52:1377-1385. [Crossref]  [PubMed]
  16. Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsøe R, Dela F. Patients with type 2 diabetes have normal mitochondrial function in skeletal mus- cle. Diabetologia. 2007;50:790-796. [Crossref]  [PubMed]  [PMC]
  17. Turner N, Heilbronn LK. Is mitochondrial dysfunc- tion a cause of insulin resistance? Trends Endocrinol Metab. 2008;19:324-330. [Crossref]  [PubMed]
  18. Morley JE,  Malmstrom TK, Rodriguez-Mañas  L, Sin- clair AJ.  Frailty, sarcopenia and diabetes.  J Am Med Dir Assoc. 2014;15:853-859.  [Crossref]  [PubMed]
  19. Thabit H, Kyaw  Tun T, McDermott J, Sreenan S. Executive function and diabetes mellitus--a stone left unturned? Curr Diabetes Rev. 2012;8:109-115. [Crossref]  [PubMed]
  20. Semba RD, Bandinelli S, Sun K, Guralnik JM, Fer- rucci L. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study. Eur J Appl Physiol. 2010;108:191-195. [Crossref]  [PubMed]  [PMC]
  21. Bianchi L,  Volpato S. Muscle  dysfunction in type  2 diabetes: a major  threat to patient’s  mobility and independence. Acta  Diabetol. 2016;53:879-889. [Crossref]  [PubMed]
  22. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, de Rekeneire N, Harris TB, Schwartz AV,  Tylavsky FA, Cho YW, Newman AB; Health, Aging, and Body Composition Study. Accel- erated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30: 1507-1512. [Crossref]  [PubMed]
  23. Mitranun W, Deerochanawong C, Tanaka H,  Suksom D. Continuous vs interval training on glycemic con- trol and macro- and microvascular reactivity in type 2 diabetic patients. Scand J Med Sci Sports. 2014;24:e69-76. [Crossref]  [PubMed]
  24. Bhanji RA, Narayanan  P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017;66:2055-2065. [Crossref]  [PubMed]
  25. Guillet C, Boirie Y. Insulin resistance: a contributing factor to age-related muscle mass loss? Diabetes Metab. 2005;31:5S20-5S26.
  26. Ozturk ZA, Türkbeyler  HA, Demir Z, Bilici  M, Kepekçi Y. The effect of blood glucose regulation on sarcopenia parameters in obese and diabetic patients. Turk J Phys Med Rehab. 2018;64:72-79. [Crossref]
  27. Yau CK, Eng C, Cenzer IS, Boscardin WJ, Rice-Trumble K, Lee SJ. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J Am Geriatr Soc. 2012;60:1215-1221. [Crossref]  [PubMed]  [PMC]
  28. Kalyani RR, Tian J, Xue  QL, Walston J,  Cappola AR, Fried LP, Brancati  FL, Blaum CS.  Hyperglycemia and incidence of  frailty and lower  extremity mobility lim- itations in older  women. J Am  Geriatr Soc. 2012;60:1701-1707. [Crossref]   [PubMed]   [PMC]
  29. Stangl  MK, Bo ̈ck eWr ,  Chubanov  V, F errari  U,  Fischereder   M,  Gudermann  T,  Hesse  E,  Meinke  P, Reincke  M,  R eisch  N,  Saller  MM,  Seissler  J1,  Schmidmaier R, Schoser B, Then C, Thorand B, Drey M. Alzheimer disease; dementia; diabetes mellitus; dynapenia; muscle; sarcopenia. Exp Clin Endocrinol Diabetes. 2018 Sep 10. [Epub ahead of print]. [Crossref]
  30. Marzetti E, Cesari M, Cal vani R, Msih id J, Tosato M, Rodrigue z-Maña Ls, Lattan zio F,  Cherubini  A, Beju it R, Di  Bari M, Magg io M,  Vellas  B, Dantoine  T,  Cruz- Jentoft  AJ,  Sieber  CC,  Freiberger  E,  Skalska  A, Grodzicki  T, S inclair  AJ,  Topinko va E,  Rýznar ovaI, Str andberg  T,  Schols  AMWJ,  Schols  JMGA,  R oller- Wirnsberger  R,  Jó nsso Pn V,  Ramel  A,  Del  Signore  S, P ahor   M,   Roubenoff   R,   Bernabei   R,   Landi   F; SP RINTT  Cons ortium.  The  “Sarc openia  and  Ph ysic al f Rail ty   IN   older   people:   multi-componenT   T reatment st rategies”  (SPRIN TT)   randomi zed  controlled   trial: case  f ind ing,  screen ing  and  cha racter ist ics  of  e ligi- ble   participants.   Exp   Gerontol.   2018;113:48-57. [C rossre f]   [ PubMed]
  31. Morley JE, Kim MJ,  Haren MT. Frailty and hor-  mones. Rev  Endocr Metab Disord. 2005;6:101-108. [Crossref]  [PubMed]
  32. Wang CP,  Lorenzo C, Espinoza SE. Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. J Endocrinol Dia- betes Obes. 2014;2.
  33. Lee CG, Boyko EJ, Barrett-Connor E, Miljkovic I, Hoffman AR, Everson-Rose SA, Lewis CE, Cawthon PM, Strotmeyer ES, Orwoll ES; Osteoporotic Frac- tures in Men (MrOS) Study Research Group. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011;34:2381- 2386. [Crossref]  [PubMed]  [PMC]
  34. Abdulla H, Phillips B, Smith K, Wilkinson D, Atherton PJ, Idris I. Physiological mechanisms of action of in- cretin and insulin in regulating skeletal muscle me- tabolism. Curr Diabetes Rev. 2014;10:327-335. [Crossref]  [PubMed]
  35. Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D. Database search of spontaneous reports and pharmacological investigations on the sul- fonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect. 2014;2:e00028. [Crossref]  [PubMed]  [PMC]
  36. Sinclair A, Vellas B. Editorial: frailty-an emerging high impact complication of diabetes requiring specific management approaches. J Nutr Health Aging. 2017;21:193-194. [Crossref]  [PubMed]
  37. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment at Rev Endocrinol. 2018;14:513-537.  Crossref] [PubMed]  [PMC]